0001209191-17-015457.txt : 20170228
0001209191-17-015457.hdr.sgml : 20170228
20170228185236
ACCESSION NUMBER: 0001209191-17-015457
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170224
FILED AS OF DATE: 20170228
DATE AS OF CHANGE: 20170228
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: MIRAGEN THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001590750
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 471187261
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: 303-531-5952
MAIL ADDRESS:
STREET 1: 6200 LOOKOUT ROAD
CITY: BOULDER
STATE: CO
ZIP: 80301
FORMER COMPANY:
FORMER CONFORMED NAME: MIRAGEN THERAPEUDICS, INC.
DATE OF NAME CHANGE: 20170213
FORMER COMPANY:
FORMER CONFORMED NAME: SIGNAL GENETICS, INC.
DATE OF NAME CHANGE: 20140710
FORMER COMPANY:
FORMER CONFORMED NAME: SIGNAL GENETICS LLC
DATE OF NAME CHANGE: 20131031
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEFKOFF KYLE
CENTRAL INDEX KEY: 0001191818
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36483
FILM NUMBER: 17650519
MAIL ADDRESS:
STREET 1: 3200 WALNUT ST
CITY: BOULDER
STATE: CO
ZIP: 80301
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-02-24
0
0001590750
MIRAGEN THERAPEUTICS, INC.
MGEN
0001191818
LEFKOFF KYLE
C/O MIRAGEN THERAPEUTICS, INC.
6200 LOOKOUT ROAD
BOULDER
CO
80301
1
0
0
0
Common Stock
2017-02-24
4
S
0
6500
14.0388
D
488031
I
See Footnote
Common Stock
2017-02-27
4
S
0
1500
13.791
D
486531
I
See Footnote
Common Stock
2017-02-28
4
S
0
2258
13.543
D
484273
I
See Footnote
Common Stock
1607437
I
See Footnote
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
All of the shares are held by Boulder Ventures VI, L.P. ("BV VI LP"). BV Partners VI, LLC ("BV VI LLC"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.75 to $13.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote.
All of the shares are held by Boulder Ventures V, L.P. ("BV V LP"). BV Partners V, LLC ("BV V LLC"), the general partner of BV V LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV V LLC, and each share voting and dispositive power over the shares held by BV V LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any.
/s/ Kassendra Galindo, as Attorney-in-Fact for Kyle A. Lefkoff
2017-02-28